SP-0502: In-vivo range estimation and adaptive particle therapy  by Lomax, T.
S238                                                                                     ESTRO 35 2016 
 _____________________________________________________________________________________________________ 
parameters accordingly and any quality assurance checks that 
are deemed necessary. Therefore the adaptive radiation 
therapy requires more resources when compare to the 
conventional image-guided radiation therapy. In fact, image-
guidance can be considered the first step in adaptive practice 
as it triggers the initial decision to adapt and provide the 3D 
volumetric images that are necessary for adaptive re-plan. 
There have been efforts to create techniques and 
technologies that can facilitate the adaptive planning. In this 
presentation, we will first discuss the state of art practice of 
adaptive proton therapy including the experience at our 
institution. We will review studies assessing the magnitude of 
intra- and inter-fractional changes and its impact on 
delivered proton dose distribution with and without adaptive 
practice. Secondly, we will present the cutting edge ideas 
and techniques that are developed specifically for adaptive 
proton lung therapy in the most recent literature.  
[1] Liu HH, Balter P, Tutt T, et al. Assessing respiration-
induced tumor motion and internal target volume using 4DCT 
for radiation therapy of lung cancer. Int J Radiat Oncol Biol 
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[2] Sonke JJ, Belderbos J. Adaptive Radiotherapy for lung 
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The finite range of protons is a two-edged sword. On one 
side, it is the raison d’etre of proton therapy, on the other, a 
potential source of uncertainties in-vivo. As such, both in-
vivo range estimates and adaptive therapy are being 
proposed and pursued for mitigating such uncertainties. 
However, sources of in-vivo range uncertainties are many, 
ranging from systematic uncertainties in the calibration of CT 
Hounsfield units to proton stopping power and inaccuracies in 
dose calculations (for convenience defined here as type I 
uncertainties) to variations in patient positioning and 
anatomy changes during the course of treatment (type 2). 
Whereas, for good quality CT data, type 1 uncertainties can 
result in range uncertainties of a few percent or millimeters 
(about 3% or 6mm in the worst case,) type 2 can result in 
range changes of the order of centimeters. In addition, type 
1 uncertainties will, to a good approximation, be similar 
across all patients of a particular indication and will remain 
the same throughout the duration of a patient’s treatment. 
Type 2 on the other hand will be patient and (potentially) 
treatment day dependent. So, what are the roles of in-vivo 
range measurement and adaptive therapy for dealing with 
these? It seems to this author that in-vivo range verification 
perhaps has a role to play in reducing type 1 uncertainties, 
whereas the best approach to type 2 has to be adaptive 
therapy. Adaptive therapy (based on regular, if not daily, 
imaging) must be pro-active (i.e. the treatment should 
ideally be adapted before delivery), whereas in-vivo range 
verification can only be (at best) reactive (e.g. may be able 
to provide a reason to interrupt a delivery if an error is 
detected). As such, the best use of in-vivo range estimation 
seems to be as part of a population based (commissioning) 
approach in order to verify that CT calibration and dose 
calculations are more and more precise, such that type 1 
uncertainties resulting from pre-treatment imaging 
(necessary to mitigate type 2 errors) can then be reduced as 
much as possible. Such an approach however puts stringent 
demands on the accuracy and precision of in-vivo range 
estimates, with in-vivo resolutions in the millimeter range 
being required in order to significantly improve these 
uncertainties. Will this ever be achievable?  
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One of the most exciting areas of basic, translational and 
clinical research in radiation oncology today is radiotherapy 
with particles, i.e. with protons or heavier ions. The main 
advantage of radiotherapy with protons compared to state-
of-the-art radiotherapy with photons is a decrease of the 
volume of normal tissues irradiated to intermediate and low 
doses, while irradiation of normal tissues to high doses or the 
conformality of the dose to the tumor are usually similar for 
protons and photons. Exceptions include situations where 
critical normal tissues can be excluded by proton therapy 
from the irradiated volume completely or to a large extent. 
The most relevant clinical research question is therefore to 
investigate whether sparing of normal tissue by proton 
therapy leads to clinical relevant benefits which balance the 
higher costs of this treatment. After demonstration of 
relevant sparing of normal tissues, further clinical studies on 
utilizing dose intensification strategies may become another 
important research avenue in those tumors where local or 
locoregional tumor control today are unsatisfactory. 
At present only few centers (often with different 
technologies and patient populations) are active in clinical 
research using protons, which makes fresh thinking on study 
design in radiation oncology necessary, as large scale 
randomized trials will not be feasible in many situations. 
Model-based approaches are a major component of the trial 
methodological portfolio, but alternatives (including 
multicenter stepwise randomized trials, pseudo-randomized 
trials and prospective matched pair trials) may be superior in 
different clinical situations. All of these approaches 
necessitate dedicated clinical research infrastructures and 
complex high-level network formation to reach the power for 
meaningful clinical trials. This also plays an important role in 
terms of radiotherapy stratified by biological parameters, 
which is anticipated to become a clinical reality in the near 
future for several tumor entities. 
Proton (or other particle) therapy holds particular promise to 
further advance personalized radiation oncology. However 
obstacles in trial design, data sampling and integration, or 
analysis may dilute the effects to such an extent that it may 
not be possible to demonstrate it according to generally 
accepted scientific standards. This would be a major hurdle 
for further implementation and reimbursement of this 
auspicious technology, and also for sound medical 
stratification of access of patients in need for this therapy. 
The lecture will discuss opportunities and problems of proton 
therapy in the context of high precision personalized as well 
as biologically stratified radiation oncology, thereby also 
touching trial design, technology development and the 
importance of network formation on a European level. 
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Small animal image guided irradiation platforms are 
revolutionizing the field of preclinical radiobiology by 
facilitating the delivery of clinically relevant irradiation 
